1. When clofibrate [ethyl 2-(4-chlorophenoxy)-2-methylpropionate] was administered subcutaneously to rats (600mg/kg per day for 5 days), the concentration of CoA and its acyl derivatives increased in several tissues. The increase in total CoA was 3.2-fold in the liver, 1.8-fold in the kidney, 2.7-fold in the heart and 2.4-fold in skeletal muscle. 2. To study the mechanism of this phenomenon, clofibrate-treated rats were injected with [3H]pantothenate intracardially and killed after 15 min, 30min, 1 and 2h and 1, 3, 5 and 7 days for the determination of the incorporation of radioactivity into CoA and its precursors. Incorporation into CoA after 2h was 6.2-fold in the liver as compared with the control values and 4.6-fold in the kidneys. 3. The disappearance of the label from CoA was very slow compared with the rate of incorporation; it exhibited exponential kinetics, and was slower in the livers of the clofibrate-treated rats (t* 18.2 days) than in the controls (t4 5.6 days). 4. The rate of CoA degradation, calculated from the calculated rate constants of the apparent first-order kinetics of the disappearance of the label and from the CoA pool sizes, was approximately the same in the clofibrate-treated animals (11.5pmol/min per g), and the controls (11.6pmol/min per g). 5. These rates of CoA degradation indicate that the effect of clofibrate on CoA concentration may be mainly due to inhibition of the enzymes of CoA degradation, although recycling of the label cannot be excluded. The increase in the rate of pantothenate incorporation into CoA suggests that clofibrate also increases the synthesis of CoA.
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CoA is an important cofactor in intermediary metabolism. The concentration of free CoA has only been demonstrated positively to function as a metabolic regulator in a few instances (see e.g. Randle et al., 1966) . Various studies (Akerboom & Zuurendonk, 1974; Soboll et al., 1976; Idell-Wenger et al., 1978) have revealed that most of the CoA and its derivatives occurs in the mitochondria and only a minimal portion is located in the cytosol. The cytosolic concentration is in the micromolar range (1-5UM) (Soboll et al., 1976) . Thus the concentration of free CoA may regulate the activity of some enzymes in the extramitochondrial compartment [e.g. acyl-CoA synthetase, which has a Km value of 8-24pM for CoA (Oram et al., 1975) ]. The variation in tissue CoA content in various nutritional and hormonal conditions (Guynn et al., 1972) similarly suggests a possible regulatory role for the CoA concentration.
It has been shown that clofibrate [ethyl 2-(4-chlorophenoxy)-2-methylpropionate], a hypolipidaemic drug, causes a multiple increase in the hepatic CoA concentration (Miyazawaetal., 197 5; Savolainen et al., 1977b) . Since clofibrate is also known to increase the rate of oxidation of fatty acids in perfused liver and liver mitochondria (Hassinen & Kahonen, 1974; Mackerer, 1977) (Nakamura et al., 1972) . The samples were stirred for 20min at 37°C and then cooled to 4°C and applied to the column. DEAE-cellulose column chromatography DEAE-cellulose was sequentially pretreated with 1 M-NaOH and 1 M-HCl and washed with water until the pH was 6.5. A portion (5 ml) of the sample was applied to the column (1 cm x 12 cm), followed by 5 ml of 1 mM-dithiothreitol. The column was then eluted with a linear 400ml gradient of 0-75mM-LiCl in 3mM-HCl/1mM-dithiothreitol (Moffatt & Khorana, 1961; Larrabee et al., 1965) . The flow rate was 4ml/min, and 4.3 ml fractions were collected.
Analytical procedures
Radioactivity. The radioactivity in the fractions from DEAE-cellulose and paper chromatography was determined in Bray's (1960) scintillation solution with a Wallac liquid-scintillation counter.
Tissue blood (haemoglobin) content. To correct the observed radioactivity of tissue pantothenic acid for interference due to the radioactivity in the blood, the blood content of the tissues was determined by measuring the haemoglobin concentrations in the tissues. Tissue samples were homogenized in 9vol. of 30mM-potassium phosphate buffer, pH 7.4, in a glass homogenizer fitted with a Teflon pestle. A 0.1 ml portion of the tissue homogenate was added to 1.0 ml of aerated reaction mixture containing 27,umol of potassium phosphate, pH7.4, 1 umol of succinate and Iumol of KCN. The absorbance difference at the wavelength pair 576-557nm was monitored in an Aminco DW-2 dual-wavelength spectrophotometer and the absorbance difference increment observed after the addition of few crystals of Na2S204 was recorded and used for the calculation of the haemoglobin content. The amount of blood in the tissues was calculated from the haemoglobin content of the tissue sample and that in a suitably diluted blood sample from the same rat, assuming that the haematocrit value for the blood in the liver is the same as in the peripheral blood. This method gave somewhat lower values than those obtained by methods using I251-labelled albumin (Abrams & Cooper, 1976) .
Determination of concentrations of CoA, acetylCoA and long-chainfatty acyl-CoA. Tissue samples for CoA and acetyl-CoA determinations were prepared as described earlier (Savolainen et al., 1977a) . Free CoA was assayed by the method of Garland (1964) , and acetyl-CoA was determined in the same assay by a subsequent addition of phosphotransacetylase (Tubbs & Garland, 1969) . Long-chain fatty acyl-CoA 1979
was determined in the HCl04-insoluble fraction of the tissue as described earlier (Savolainen et al., 1977a) . Miscellaneous procedures. Thiol groups were determined as described by Ellman (1959) , total phosphorus by the method of Chen et al. (1956) , and 4'-phospho[3H]pantetheine was prepared from [3H]-CoA by using nucleotide pyrophosphatase (EC 3.6.1.9) (Loewen, 1977) . Pantothenate and 4'-phosphopantetheine were separated by ascending paper chromatography at 4°C in a solvent containing butan-1-ol/acetic acid/water (5:2:3, by vol.) essen- Fraction no. Fig. 1 and phosphorus, and its elution characteristics were identical with those of 4'-phosphopantetheine. Since the separation of peaks II and III was incomplete, the contents of these combined peaks were further analysed by paper chromatography, which separated out pantothenate and 4'-phosphopantetheine (Fig. 2) . Peak IV eluted in the column chromatography (Fig. 1) Temporalpattern oflabel incorporation. Fig. 3 shows the temporal pattern of incorporation of the label into the pantothenic acid derivatives in the rat liver and kidney after an intracardial injection of [3H]-pantothenate. In both tissues the radioactivity in Fraction no. Fig. 2 . Separation of the components ofpeaks II and IIIfrom column chromatography bv paper chromatography DEAE-cellulose column chromatography fractions containing peaks II and III were pooled, freeze-dried and dissolved in 1 ml of water; 0.1 ml was applied to Whatman no. I paper and ascending paper chromatography carried out in a solvent containing butan-l-ol/acetic acid/water (5:2:3, by vol.). Shaded areas above the chromatogram show the migration of CoA, 4'-phosphopantetheine and pantothenic acid standards. *, Clofibrate-treated rat; 0, control rat. Fig. 1 pantothenic acid decreases sharply after 1 h (Figs. 3a  and 3d ), whereas that of 4'-phosphopantetheine, an intermediate of CoA synthesis, increases markedly during the first hour and continues to rise slowly up to 2h in the liver (Fig. 3b) . In the kidney the increase ceases after 30min, after which the radioactivity in 4'-phosphopantetheine assumes an almost constant value (Fig. 3e) . The radioactivity incorporated into 4'-phosphopantetheine (in d.p.m./g wet weight) within 2h is 5.5-fold in the liver and 3.8-fold in the kidney ofthe clofibrate-treated rats compared with that in the control values.
Figs. 3(c) and 3(f) represent the radioactivity incorporated into CoA over 2 h in the liver and kidney respectively, that in the clofibrate-treated rats being Vol. 182 6.2-fold in the liver and 4.6-fold in the kidney compared with that in the controls. In terms of specific radioactivity these ratios are smaller, 2.0 in the liver and 3.8 in the kidney.
The labelled pantothenate was taken up into tissues rapidly, so that at 30min the blood radioactivity per unit volume was only 22 and 7 % ofthat in the liver and 4 and 4.5 % of that in the kidneys in the control and clofibrate-treated rats respectively. Thus there can be said to have been little distortion of the determination of tissue pantothenate by intravascular pantothenate.
CoA turnover
The disappearance of the label from CoA is very slow compared with the rate of incorporation. Fig. 4 at zero time and with 375nmol of calcium D(+)-pantothenate 3h later. Liver and kidney samples were taken 1, 3, 5 or 7 days after the last injection. CoA and its precursors were separated by DEAE-column chromatography as described in the Experimental section. The lines were fitted to the experimental data by least-squares regressionanalysis. (a) Liver; (b) kidney. *, Clofibrate-treated rats; 0, control rats.
shows the least-squares regression lines for log (specific radioactivity of CoA) versus time. The lines represent half-lives of 18.2 days (r = 0.88, n = 5, P <0.05) and 5.6 days (r = 0.91, n = 6, P<0.01) in the liver and 6.9 days (r = 0.85, n = 5,P<0.1) and 4.2 days (r = 0.96, n = 5, P<0.01) in the kidney for the clofibrate-treated and control rats respectively.
The disappearance of the label is exponential obeying the equation: a = ao . e`k where ao is the initial specific radioactivity, a is the specific radioactivity at time t, and k is the first-order velocity constant ofthe assumed relation da/dt = -ka. The turnover of CoA can be calculated from the tissue concentration of CoA and the constant k. In these experiments on the CoA turnover, clofibrate injections were continued for the 7-day period of liver sampling. The total CoA concentration of the liver remained constant during this period. The constants k obtained here were 0.264x 10-and 0.859x 10-4min-' in the liver and 0.697x 10-and 1.15x 10 min-' in the kidneys of the clofibrate-treated and control rats respectively. The turnover rate of CoA in the liver was therefore 11.5pmol/min per g in the clofibrate-treated rats and 11.6pmol/min per g in the control rats, and that in the kidney 1.3 and 12.2 pmol/ min per g respectively.
Discussion
The present results can be interpreted as indicating that the cellular CoA concentration is effectively regulated and that this regulation can be influenced by a hypolipidaemic drug, with the phenomenon observed perhaps partly explaining the pharmacological effects of the drug.
There are also previous reports that other hypolipidaemic drugs cause similar effects. 2-Methyl 2-[4-(1, 2,3, 4 -tetrahydro -1 -naphthyl) phenoxy] propionic acid, for instance, is known to increase the hepatic content of CoA derivatives (Schacht & Granzer, 1970) .
In the present case, the results are equivocal in that they apparently demonstrate an increase in the rate of CoA synthesis and a decrease in its rate of degradation. One should bear in mind, however, that owing to the rapid disappearance of pantothenic acid from the blood and tissues, it was'not possible to measure the specific radioactivity of the precursor of the pathway of CoA synthesis. The surprising agreement between the results on CoA turnover in the clofibratetreated and control rats, however, suggests that it is more likely that under these experimental conditions the CoA concentration was regulated by the rate of CoA degradation.
The total CoA concentration is obviously under 1979 physiological regulation, as it is affected by food deprivation (Guynn et al., 1972) and insulin deficiency (Smith et al., 1978 (Gear et al., 1974) concomitantly with a 40 % increase in the liver weight (Hawkins et al., 1974) , which means that the hepatic concentration of mitochondria increases. On the other hand, mitochondrial protein synthesis has been reported to diminish and the activity of mitochondrial proteinases to be inhibited (Gear et al., 1974) It is also known that clofibrate induces a proliferation of peroxisomes (Hess et al., 1965) in the liver.
Moreover, kidney cells also contain peroxisomes. It remains to be established whether a portion of the newly synthesized CoA is located in the hepatic or renal peroxisomes.
It has been observed both in isolated mitochondria and in perfused rat livers that clofibrate increases the rate of fatty acid oxidation (Hassinen & Kahonen, 1974; Mackerer, 1977) , and it is commonly accepted that the rate-limiting step in the oxidation of fatty acids is the synthesis of acyl-carnitine by CoAcarnitine acyltransferase, the activity of which increases during clofibrate treatment (Daae & Aas, 1973) . The role ofthe concentration offree CoA in the regulation of fatty acid oxidation is not known exactly, but it has been postulated that the cytosolic carnitine/CoA ratio may determine the fate of fatty acids in the oxidative or esterification pathway, at least in the heart (Oram et al., 1975) , and it has been calculated that the cytosolic free CoA concentration is probably below the Km of fatty acid activation (Idell-Wenger et al., 1978) . Fatty acid activation may therefore be regulated by the CoA concentration. It may be concluded from the above that the effects of clofibrate on the CoA concentration could explain the increased uptake and activation of fatty acids in tissues, but not necessarily the increased oxidation of fatty acids.
